Dr. Anna Lembke on Huberman Lab: How to Beat Addiction

Dopamine is always being released at a tonic baseline. High‑reward activities (drugs, binge‑watching, social media, gambling, etc.) cause large upward deviations, and the brain compensates by downregulating dopamine receptors and transmission. Over time, this resets the baseline lower, creating an anhedonic, “nothing feels good” state marked by anxiety, irritability, insomnia, and preoccupation with using again. Recognizing this helps reframe addiction as a brain-based disease rather than a simple failure of willpower.

Pleasure and pain are processed in overlapping brain regions and operate like a seesaw that strives for homeostasis. A pleasurable stimulus tips the balance toward pleasure; afterward the brain overcorrects toward pain, often below baseline. That “mini‑deficit” is felt as wanting more—the core of craving and compulsion. Understanding this allows people to anticipate the comedown, wait it out, and avoid the reflexive “just one more” cycle.

Clinically, Lembke finds that it typically takes about 30 days of zero contact with the addictive substance or behavior for dopamine systems to re‑equilibrate. Patients usually feel worse before better: the first ~2 weeks are marked by heightened anxiety, agitation, sleep problems, irritability, and low mood. Around week three, mood and enjoyment start to improve, and by week four many can again derive pleasure from simple, everyday experiences (e.g., a good cup of coffee). Going in with this roadmap improves adherence.

Some individuals are wired with higher impulsivity—acting on thoughts quickly—and a stronger need for challenge, novelty, and intensity. In evolutionary contexts these traits could be advantageous; in modern environments saturated with instant rewards and minimal survival demands, they become liabilities. People whose brains are “not well‑suited to this world” often experience normal life as boring and are more likely to seek extreme dopamine sources, making prevention and treatment strategies that add healthy friction (difficult goals, real‑world challenges) especially important.

Triggers—people, places, emotions, even thoughts about the drug—cause a small anticipatory dopamine rise followed by a dip below baseline, which feels like craving and propels action. This process also explains why good news or major ‘wins’ can be dangerous: the reward and the relaxation of hypervigilant self‑monitoring lower defenses, and the dopamine surge can reopen the door to drug seeking. People in recovery need specific plans for both stress‑related and success‑related triggers (extra meetings, support, barriers to access).